Condition: Small Cell Lung Cancer · Neuroendocrine Carcinoma · Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.
This description comes directly from the study's public registry record.
Hewen Yin · +86-02158942758 · yinhw@zelgen.com
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05978284